Open AccessPharmacogenomic determinants of response to cardiovascular drugs
Author(s) -
Karmen Stankov,
Bojan Stanimirov,
Momir Mikov
Publication year - 2015
Publication title -
medicinski pregled
Language(s) - English
Resource type - Journals
eISSN - 1820-7383
pISSN - 0025-8105
DOI - 10.2298/mpns1508259s
Subject(s) - medicine , pharmacogenomics , pharmacogenetics , intensive care medicine , precision medicine , clopidogrel , warfarin , personalized medicine , drug response , adverse effect , pharmacotherapy , bioinformatics , drug , pharmacology , atrial fibrillation , myocardial infarction , pathology , biochemistry , chemistry , biology , genotype , gene
Cardiovascular diseases are the leading cause of morbidity and mortality worldwide. Despite considerable advances in cardiovascular pharmacology, significant inter-individual variability in response to drugs affects both their efficacy and safety profile. Drug-gene associations have emerged as important factors determining a spectrum of response to therapy. Pharmacogenomic interactions in cardiovascular medicine are also involved in etiology of adverse effects that may be life-threatening, such as statininduced myopathy or a hemorrhage/thrombosis event during anticoagulant therapy. Introduction of genetic tests prior to the initiation of therapy and implementation of genetically-guided therapy represent a step forward to achieving a goal of individualized medicine in cardiology, already present in recommendations for warfarin and clopidogrel. However, further investigations addressing genomic predictors of variability in response to drugs are still needed and translating these findings into routine clinical practice remains a substantial challenge.